Equillium (EQ) Net Income towards Common Stockholders (2018 - 2026)

Equillium (EQ) reported Net Income towards Common Stockholders of -$5.3 million for Q1 2026, up 39.05% year-over-year from -$3.8 million in Q1 2025, and down 134.71% quarter-over-quarter from $15.3 million in Q4 2025.

Equillium (EQ) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends

Equillium (EQ) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$5.3 million in Q1 2026.

  • Net Income towards Common Stockholders for Q1 2026 came in at -$5.3 million, up 39.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$476000.0 (up 96.61% YoY), and the FY2025 annual result was -$22.4 million, down 177.65% from the prior year.
  • Net Income towards Common Stockholders eased to -$5.3 million in Q1 2026 per EQ's latest filing, from $15.3 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $63.2 million in Q4 2022 and troughed at -$37.4 million in Q1 2022.
  • A 5-year average of -$1.9 million and a median of -$3.9 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders jumped 693.59% in 2022, then tumbled 61900.0% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $63.2 million in 2022, then slumped by 103.68% to -$2.3 million in 2023, then plunged by 149.1% to -$5.8 million in 2024, then surged by 363.57% to $15.3 million in 2025, then slumped by 134.71% to -$5.3 million in 2026.
  • Business Quant data shows EQ's Net Income towards Common Stockholders at -$5.3 million in Q1 2026, $15.3 million in Q4 2025, and -$4.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.56 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 2.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.63 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 Equillium 293.17 Mn 232.78 Mn - -5.30 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -5.30 Mn
Dec 31, 2025 15.27 Mn
Sep 30, 2025 -4.34 Mn
Jun 30, 2025 -6.11 Mn
Mar 31, 2025 -8.70 Mn
Dec 31, 2024 -5.79 Mn
Sep 30, 2024 -7,000.00
Jun 30, 2024 468,000.00
Mar 31, 2024 -2.73 Mn
Dec 31, 2023 -2.33 Mn
Sep 30, 2023 -3.71 Mn
Jun 30, 2023 -3.34 Mn
Mar 31, 2023 -3.94 Mn
Dec 31, 2022 63.18 Mn
Sep 30, 2022 -13.66 Mn
Jun 30, 2022 -14.13 Mn
Mar 31, 2022 -37.42 Mn
Dec 31, 2021 -10.64 Mn
Sep 30, 2021 -10.12 Mn
Jun 30, 2021 -9.10 Mn